Investors Seek Justice: Soleno Therapeutics Faces Class Action Over Alleged Fraud Soleno Therapeutics, Inc. faces a securities fraud lawsuit as investors claim misrepresentations about DCCR's safety. Affected shareholders may seek to lead the class action.

Investors Seek Justice: Soleno Therapeutics Faces Class Action Over Alleged Fraud #United_States #New_York #VYKAT_XR #Soleno_Therapeutics #DCCR

Soleno Therapeutics Confronts Legal Action as DCCR Launch Faces Troubles Soleno Therapeutics, facing a class action lawsuit, confronts challenges regarding the launch of its hyperphagia drug, DCCR, and its market impact.

Soleno Therapeutics Confronts Legal Action as DCCR Launch Faces Troubles #United_States #San_Francisco #VYKAT_XR #Soleno_Therapeutics #DCCR

Investors of Soleno Therapeutics, Inc. Encouraged to Join Securities Fraud Class Action Shareholders of Soleno Therapeutics who suffered losses now have the chance to lead a securities fraud lawsuit against the company. Time-sensitive information.

Investors of Soleno Therapeutics, Inc. Encouraged to Join Securities Fraud Class Action #United_States #Los_Angeles #Securities_Fraud #Soleno_Therapeutics #DCCR

Investors Unite Against Soleno Therapeutics Over Alleged Clinical Trial Fraud A class action lawsuit against Soleno Therapeutics has been initiated by investors who allege that clinical trial misrepresentations led to financial losses.

Investors Unite Against Soleno Therapeutics Over Alleged Clinical Trial Fraud #United_States #New_York #Class_Action #Soleno_Therapeutics #DCCR

Soleno Therapeutics Investors Alerted: Possible Class Action Lawsuit Participation Investors who suffered losses from Soleno Therapeutics' misleading statements may join a class action lawsuit. Deadline for participation is May 5, 2026.

Soleno Therapeutics Investors Alerted: Possible Class Action Lawsuit Participation #United_States #New_York #Gross_Law_Firm #Soleno_Therapeutics #DCCR

Important Notice for Soleno Therapeutics Investors: Class Action Lawsuit Deadline Approaches Investors in Soleno Therapeutics Inc. are urged to take action by May 5, 2026, regarding a class action lawsuit alleging securities fraud.

Important Notice for Soleno Therapeutics Investors: Class Action Lawsuit Deadline Approaches #United_States #Class_Action #New_Orleans #Soleno_Therapeutics #DCCR

Legal Action Against Soleno Therapeutics Raises Concerns Over Clinical Trial Integrity and Investor Trust Investors in Soleno Therapeutics, Inc. face potential losses due to allegations of sham clinical trials affecting drug approval. A class action lawsuit highlights serious concerns over the data integrity surrounding DCCR.

Legal Action Against Soleno Therapeutics Raises Concerns Over Clinical Trial Integrity and Investor Trust #USA #New_York #Clinical_Trials #Soleno_Therapeutics #DCCR

Class Action Lawsuit Filed Against Soleno Therapeutics for Investor Misleading Practices Robbins LLP has launched a class action against Soleno Therapeutics for failing to disclose crucial safety concerns in its Phase 3 trials. Investors may be eligible.

Class Action Lawsuit Filed Against Soleno Therapeutics for Investor Misleading Practices #United_States #San_Diego #Robbins_LLP #Soleno_Therapeutics #DCCR

DCCR Sustains Durable Hyperphagia Control in Prader-Willi Syndrome Continued DCCR significantly limited hyperphagia worsening vs withdrawal of DCCR and placebo initiation in Prader-Willi Syndrome (PWS).

Continued #DCCR significantly limited #Hyperphagia worsening vs withdrawal of DCCR and placebo initiation in Prader-Willi Syndrome (#PWS). Study in @endosocjournals.bsky.social @endocrinesociety.bsky.social

Read more: https://bit.ly/3Zj11Y2

#RareDisease #PraderWilliSyndrome #Endocrinology